The technology

eDC technology

Engineered dendritic cells (eDC): renewable human antigen-presenting cell lines established from primary blood cells.

  • Dendritic cell identity: lineage negative (CD3, CD14, CD19, CD56), CD11c and CD205 positive.
  • Mature, activated phenotype maintained in culture: CD80, CD86, CD70, HLA-DR, CCR7.
  • Expands in culture, so one defined line can supply repeated experiments.
  • Accepts a defined antigen and agreed gene modifications, including knockout.
Explore eDC technology

The discovery workflow

APC drug discovery platform

A workflow in which eDCs present candidate antigens to T cells, followed by functional testing against paired target cells.

  • Question: is the antigen presented, recognized and functionally relevant?
  • System: antigen-expressing eDC, responder T cells and paired target cells with antigen and HLA controls.
  • Output: antigen- and HLA-dependent response data, available before a program commits to a drug modality.
Explore the platform
Six-step workflow: tumor samples, candidate neoantigens, antigen presentation on eDC, antigen target validation, tumor-specific antigen spread and cancer therapy. Validated antigens inform peptide–HLA-dependent modalities (DC vaccines, mRNA neoantigen vaccines, TCR-T, TIL, antibodies to the peptide–HLA complex) and surface target modalities (CAR-T, BiTE, ADC). Stages 5 and 6 are downstream biology and development beyond the assay. Released tumor antigen is taken up by dendritic cells.
Where eDC technology fits. Antigen presentation on eDC connects candidate antigens to target validation. Peptide–HLA-dependent modalities, including antibodies to the complex, are tested directly; surface target modalities use the validated antigen list. Conceptual workflow.

Why this supports drug discovery

Prediction needs functional testing

In the TESLA consortium, 37 of 608 tested neoantigen candidates (6%) were recognized by T cells. Functional testing separates presented antigens from predicted ones. [12]

One defined APC

A renewable line removes donor-by-donor APC preparation as one source of variation. Responder cells, targets and handling still need matched controls.

HLA controls

Paired targets with and without antigen or HLA, plus HLA blockade, show whether a response depends on the intended peptide–HLA complex.

Gene editing in the APC

Gene knockout or overexpression in the APC tests which APC factors shape priming, with a matched control line.

Antibody-directed programs

Once an immunogenic peptide–HLA complex is known, it can define the target for a complex-specific antibody and for CAR-T, ADC or T cell engager formats built on it. Targeting the complex can add specificity over a surface protein. Presentation on the tumor still has to be shown.

Biologic screening

eDCs keep a mature phenotype with costimulatory molecules such as CD40. Agonist and checkpoint antibodies, for example anti-CD40 and anti-PD-L1, can be compared by their effect on APC activation and T cell priming, once target expression is confirmed on the line used.

How a project starts

Project workflow

CrossRelay is a focused platform CRO. Projects start with one question, and each scope states the controls, acceptance criteria and reported limits before work begins.

01

Scope

Antigen, HLA context and the decision the data should support, with controls and acceptance criteria agreed in writing.

02

Pilot

A bounded first study sized to answer one question on an eDC configuration for your antigen.

03

Expand

Candidate panels, custom eDC lines from your PBMCs, or biologic screening, based on the pilot result.

eDC technology is described in peer-reviewed work: Wu et al., PNAS 2018, and Zhao et al., Cancer Immunology, Immunotherapy 2025. See publications

Products & custom development

Product information
01

Antigen-expressing eDC lines

Renewable human APC configurations expressing a specific antigen.

Explore eDC lines
02

Paired cellular assay systems

An eDC component and a paired target cell model for functional assessment.

Explore assay systems
03

Cytokines for culture

Cytokines for T cell and NK cell growth, dendritic cell differentiation and culture support.

Explore cytokines
04

Custom eDC engineering

Customer PBMCs, defined antigen requirements and genetic modifications, including KO.

Explore custom projects

Cancer immunotherapy & APC biology

The science
behind the system

Recent immunotherapy progress, the barriers that remain, and the DC–antigen–T cell relationship that underlies antigen-specific research.

DC–T cell interaction: recognition, signaling and function. 100-second conceptual animation with narration and on-screen explanations. Receptor engagement, intracellular signals and cytokine movement are illustrated; this is not live-cell microscopy.
Read the narration transcript

Dendritic cells connect antigen detection with T cell responses. At their contact site, called the immunological synapse, several molecular interactions work together.

A peptide displayed by an HLA molecule engages a compatible T cell receptor. Class I presentation is recognized by CD8 T cells. Class II presentation is recognized by CD4 T cells.

Recognition alone does not explain the full response. CD80 and CD86 can engage CD28, while adhesion molecules help maintain contact. Signals then travel into the T cell.

Activated helper T cells can provide CD40 ligand to dendritic cells. Cytokines shape the response. IL-12 can favor type 1 immunity. IL-2 supports T cell growth, with its source depending on the experimental context.

Inhibitory interactions also matter. PD-L1 binding PD-1 can reduce T cell signaling. Activation reflects the balance of antigen recognition, costimulation, cytokines and inhibitory signals.

For drug discovery, measure more than cell numbers. Test antigen and HLA dependence, cytokine responses, and activity against paired target cells. These complementary readouts connect the mechanism to the biological question.

Functional data

Three readouts for
three separate questions

Antigen expression, T cell activation and target cell cytolysis answer different questions. The linked data show the controls each readout needs.

01Antigen expression

Is the antigen present in the eDC and the target?

02T cell activation

Is an antigen-specific response induced?

03Target cytolysis

Does killing depend on the antigen and HLA context?

Conceptual framework; not experimental data.

Scientific insights

Browse the resource library

About CrossRelay

Built by the scientists who invented eDC technology

CrossRelay supports researchers who investigate immune mechanisms, identify drug targets and develop cancer immunotherapies.

About CrossRelay

Scientific support

Research tools, study design advice and functional data for antigen presentation studies.

Discuss your research configuration

Antigen, HLA context, paired targets and custom genetic modifications.

Scientific support